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Abstract
Purpose—The osteocyte exerts important effects on bone remodeling but its rhythmicity and 
effect on the rhythms of other bone cells are not fully characterized. The purpose of this study was 
to determine if serum sclerostin displays rhythmicity over a 24-hour (h) interval, similar to that of 
other bone biomarkers.
Methods—Serum sclerostin, FGF-23, CTX, and P1NP were measured every 2 hours over a 24-h 
interval on 10 healthy men aged 20-65 years. Maximum likelihood estimates of the parameters in 
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a repeated measures model were used to determine if these biomarkers displayed a diurnal, 
sinusoidal rhythm.
Results—No discernible 24-h rhythm was identified for sclerostin (p = 0.99) or P1NP (p = 0.65). 
CTX rhythmicity was confirmed (p < 0.001), peaking at 05:30 (range 01:30–07:30). FGF-23 levels 
were also rhythmic (p < 0.001) but time of peak was variable (range 02:30-11:30). The only 
significant association identified between these four bone biomarkers was for CTX and P1NP 
mean 24-h metabolite levels (r = 0.65, p = 0.04).
Conclusions—Sclerostin levels do not appear to be rhythmic in men. This suggests that in 
contrast to CTX, serum sclerostin could be measured at any time of day. The 24-h profiles of 
FGF-23 suggest that a component of osteocyte function is rhythmic but its timing is variable. Our 
results do not support the hypothesis that osteocytes direct the rhythmicity of other bone turnover 
markers (CTX), at least not via a sclerostin mediated mechanism.
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Introduction
Osteoblasts and osteoclasts display daily patterns with circulating markers of bone 
resorption and, to a lesser extent, bone formation (i.e., osteocalcin), peaking in the early 
morning with a nadir in the late afternoon [1,2]. Daily patterns are likely important for 
normal bone remodeling, but may differ between bone cells. For example, the rhythm of the 
bone resorption marker serum C-terminal cross-linked telopeptide of type I collagen (CTX) 
is influenced by food intake (possibly mediated by endocrine and nutritional signals such as 
glucagon-like peptide 2, GLP-2) [1,3,4], while food has little influence on the less 
pronounced rhythm of bone formation markers [4]. Overall, bone turnover marker (BTM) 
rhythmicity in humans appears to be largely independent of posture [1], sex [1], and normal 
light/dark cycles [4], and therefore may reflect internal circadian rhythmicity.
Although the osteocyte has been described as the “orchestrator” of bone remodeling [5], it’s 
role in the daily rhythmicity of other BTMs is uncertain. Osteocytes regulate bone resorption 
and bone formation via paracrine and endocrine effects on osteoclasts and osteoblasts [5]. 
Therefore, it is possible that the osteocyte and its secreted protein sclerostin also display a 
physiologically important rhythm that “orchestrates” or influences the rhythmicity of other 
bone cells. Osteocytes secrete fibroblast growth factor 23 (FGF-23) and sclerostin to 
regulate phosphate/vitamin D metabolism and bone turnover. Intact FGF-23 levels 
demonstrate diurnal variation, peaking in the early morning [6,7]. However, the rhythmicity 
of sclerostin, and therefore the osteocyte, remains incompletely characterized, as does the 
osteocyte’s role in the rhythms of other bone cell physiology. Understanding the role of the 
osteocyte and sclerostin in the generation of bone remodeling rhythms is key to 
understanding the biology of bone turnover rhythmicity and how circadian perturbations (i.e. 
shift work, jet lag) could lead to metabolic bone disease.
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We sought to determine whether a 24-hour (h), diurnal rhythm exists for sclerostin, a marker 
of osteocyte function, and if so, how that rhythm relates to the 24-h rhythms of other 
biomarkers of bone metabolism [CTX, N-terminal propeptide of type I procollagen (P1NP), 
FGF-23].
Methods
Study Participants and Study Design/Experimental Protocol
For this observational study, frozen serum samples from a previous prospectively performed 
experiment were used. As reported by our group [8] and Buxton et al [9], 11 healthy, adult 
men, aged 20-65 years were recruited. Participants were admitted to the Intensive 
Physiological Monitoring Unit of the Center for Clinical Investigation at Brigham and 
Women’s Hospital between 2007-2010. A ≥ 21-day at home run-in stage of 10-h sleep 
opportunity per night (verified by wrist actigraphy, sleep diary, and timestamped call-ins) in 
addition to ≥10 h/day sleep opportunity for three days in the lab prior to sampling ensured 
that individuals were fully sleep satiated at the time of sampling (see Fig 1 study protocol; 
adapted from Buxton et al [9]). Serum used for this study was obtained hourly (including 
during sleep) across a baseline 24-h interval on days 5 to 6 from an intravenous catheter. 
Participants received an isocaloric, controlled nutrient diet (55-60% carbohydrate, 15-20% 
protein, 15-30% fat) composed of 3 meals/1 snack and ≥2.5 liters of fluid per 24 h. Wake 
time was spent in constant dim light (<15 lux) and sleep opportunities in constant darkness 
(<0.02 lux).
Ten men with available serum were used for the current study (one man was excluded for an 
incomplete 24-h serum profile). Self-reported race/ethnicity were as follows: White/not 
Hispanic or Latino n = 7, White/Hispanic n = 2, Asian & White/not Hispanic or Latino n=1. 
All participants were normal sleepers as verified with a polysomnographically recorded 
adaptation night and questionnaires [9]. Since individual bed times varied, laboratory sleep 
opportunities and blood sampling were performed relative to the midpoint of the habitual 
sleep opportunity in order to align participants’ collections relative to sleep/wake and light/
dark cycles. Core body temperature minimum, a robust measure of circadian phase, reflected 
excellent subsequent alignment of the ten profiles (all ten men varied within a 40-minute 
interval; older men varied within 16-minutes). Times presented here are in “relative clock 
hour” using 24-h military time with time relative to breakfast (average breakfast time = 
09:27, SD 3 min).
All participants [9] provided written informed consent. All procedures were approved by the 
Partners Human Research Committee and were conducted in accordance with the 
Declaration of Helsinki. The current analyses were performed at OHSU using de-identified 
samples, were deemed non-human subjects research by OHSU IRB# 00010357, and were 
approved by Brigham and Women’s Hospital IRB.
Assays
Assays were performed on samples from every other hour (q2 h samples) for each 
participant, as this was frequent enough to provide adequate determination of a rhythm, if 
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present. If a sample from the preferred hour was missing, a sample from the adjacent hour 
was used, which was necessary in approximately 15% of samples. Assays were performed at 
the Oregon Clinical and Translational Research Institute (OCTRI) laboratory at Oregon 
Health & Science University (OHSU) in 2015. Each individual’s samples were run in the 
same assay to minimize inter-assay variability. Serum sclerostin levels were measured in 
duplicate on previously unthawed samples stored below −80°C until assay by ELISA 
(ALPCO/Biomedica, Salem, NH). Interassay coefficient of variation (CV) was 7.5% at 60.9 
pmol/L. Intra-assay CV was 7% at 33.6 pmol/L and 5% at 118.8 pmol/L. FGF-23 was 
measured immunometrically (Kainos Laboratory, Tokyo, Japan) in serum that had 
undergone one freeze/thaw cycle. Interassay CV was 4.9% at 48.4 pg/mL. Intra-assay CV 
was 3% at 14.2 pg/mL and 2.8% at 28.7 pg/mL. The intact trimer of P1NP was measured by 
immunoassay (Orion Diagnostica, Finland) in duplicate on serum that had undergone one 
freeze/thaw cycle. Interassay CV was 2.1% at 38.3 μg/L and 3.0% at 118 μg/L. Intra-assay 
CV was 5.4% at 23.6 μg/L, 3.2% at 33.1 μg/L, 5.4% at 53.1 μg/L, and 9.6% at 149.2 μg/L. 
CTX was measured by ELISA (Immunodiagnostic Systems, United Kingdom) on serum that 
had undergone one freeze/thaw cycle. Interassay CV was 15.7% at 0.18 ng/mL and 12.7% at 
0.87 ng/mL. Intra-assay CV was 3% at 0.121 ng/mL, 1.7% at 0.444 ng/mL, and 1.8% at 1.96 
ng/mL. All intra-assay CVs are as reported per manufacturers’ specifications. Values were 
averaged to obtain a final result for the biomarkers measured in duplicate (sclerostin, P1NP).
Statistical Analysis
The primary objective of this study was to determine the presence/absence of diurnal 
rhythmicity in sclerostin. To this end, we fit a cosinor model [10] controlling for age. 
Secondary outcomes were to evaluate metabolite associations and to confirm the presence/
absence of rhythmicity for the other bone biomarkers, as internal validation of study 
conditions. No adjustments were made for multiple comparisons because these analyses 
were intended to be hypothesis generating.
Maximum likelihood (ML) estimates of the parameters in a repeated measures analysis were 
used to determine if a metabolite displayed a diurnal, sinusoidal rhythm with one or two 
harmonics, conditioned on age (Equation 1).
Equation 1
where c1=cos((h*2*π)/24) and s1=sin((h*2* π)/24) estimate the first harmonic, 
c2=cos((h*2*π)/12) and s2=sin((h*2* π)/12) estimate the second harmonic, h is the hour, 
AGE is an indicator variable for older vs. younger men, M is the mesor (midline statistic of 
rhythm), and β and γ are the parameters that estimate the amplitude ((β2 + γ2)1/2) and 
acrophase (arctan(γ/β)) for each harmonic in the cosinor model. “Harmonic” refers to the 
number of oscillations in the 24-h interval, the fundamental period for circadian rhythm. The 
first harmonic has period = 24, frequency = 1/24; the second harmonic has period = 12, 
frequency = 1/12 [10].
After visually inspecting the raw data at the individual and group levels, parameters were 
estimated at the group level to determine rhythmicity; that is, to estimate the joint 
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significance of the parameters β1 and γ1 and β2 and γ2 in equation 1. Rhythmicity, or 
significance of each harmonic for each metabolite was tested using the joint null hypothesis 
Ho: β = γ = 0 [10]. The power of ML repeated measures approach (performed using PROC 
MIXED in SAS) lies in its ability to incorporate all available longitudinal data even in the 
unbalanced case, that is, when some observations are missing. This procedure allows for the 
specification of an error structure to accommodate unevenly spaced observations.
The presence of a pattern in a metabolite’s daily peak was also tested by estimating the time 
of maximum observed level using the by individual option in the estimation for equation 1 
for rhythmic metabolites and applying the Rao test [11] for equal spacing along the 
circumference of a circle (analyzed using R [12] and plotted using Microsoft Excel).
Peak, nadir, mesor, and amplitude (± standard deviation) for metabolites with confirmed 
rhythmicity were estimated using the model described by equation 1, retaining the second 
harmonic and age if significant (p < 0.05). The nadir and peak/acrophase represent the 
minimum and maximum metabolite level on the regression curve, respectively. Amplitude is 
defined as half the distance between the nadir and peak. Mesor is the average biomarker 
level over 24 h for bone biomarkers displaying a 24-h rhythm. A mean level is noted for 
non-rhythmic biomarkers.
Spearman’s correlation coefficients were used to test the association between mean 24-h 
metabolite levels (all) and peak levels (for rhythmic metabolites). Spearman’s was chosen 
over Pearson correlation because the analysis was performed for N = 10 individuals.
Except where noted, all analyses were conducted using SAS software version 9.3 (SAS 
Institute Inc., Cary, NC, USA). Figures were generated using GraphPad Prism 7.02 
(GraphPad Software, La Jolla, CA), Microsoft Excel 2016, and Adobe Photoshop CC 2017.
Results
The 10 participants included 6 younger (20-27 years, mean 23.5 years) and 4 older (55-65 
years, mean 58.75 years) healthy men. All 24-h diurnal profile parameters from the cosinor 
model fit are presented in Table 1. Fig 2a-d displays 24-h serum profile data for each of the 4 
biomarkers (see Fig 2 Legend).
No discernible rhythm was identified for serum sclerostin over 24 hours (Table 1, Fig 2a; p = 
0.99 for Ho:β=γ=0 conditioned on age). Mean sclerostin values were higher in the older 
compared to the younger men (meanolder = 39.95 ± 4.18 pmol/L vs. meanyounger = 23.77 
± 2.70 pmol/L, p = 0.005; Fig 2a).
CTX displayed the most robust rhythm (Fig 2b) with a peak occurring at 05:30 (range 
01:30–07:30) and a nadir at 13:30 (p <0.001 for Ho: β = γ = 0 on both harmonics; relative 
clock time; Rao spacing test p < 0.001). The best fit for CTX was a 2-harmonic model 
adjusted for age. A sinusoidal rhythm was consistently seen in all individuals in raw and 
fitted data (Fig 2b). Visually, CTX amplitude appeared larger in younger compared to older 
men (Fig 2b), but this difference was not statistically significant (p > 0.07). The clear 
sinusoidal rhythm of CTX is in contrast to the relatively flat 24-h serum P1NP profile (p = 
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0.65 for Ho:β=γ=0 in the cosinor model conditioned on age; Fig 2c). However, Rao spacing 
test for P1NP in polar plot suggested time of peaks were significantly clustered (p< 0.01), 
and a very small amplitude sinusoidal curve can be seen visually in the fitted curve when the 
y-axis has a smaller range (Online Resource Fig 1). CTX and P1NP levels were higher in the 
younger, compared to older men (CTX mesoryounger = 0.89 ± 0.10 ng/mL vs. CTX 
mesorolder = 0.42 ± 0.15 ng/mL, p = 0.01; P1NP meanyounger = 73.35 ± 4.96 μg/L vs. P1NP 
meanolder = 52.18 ± 7.69 μg/L; p = 0.03).
FGF-23 was rhythmic (p<0.001), best fit with one harmonic and no adjustment for age (Fig 
2d). The estimated acrophase was approximately 08:30 (relative clock time) and the nadir 
occurred at 20:30. There was more variation in the time of FGF-23 peak between individuals 
(range 02:30-11:30) compared to that of CTX as seen in the polar plots in Fig 2 (right panel) 
and as suggested by the corresponding p-values (p < 0.001 for CTX vs. p < 0.10 for FGF-23 
by Rao spacing test). Unlike the other bone biomarkers in this study, FGF-23 levels did not 
vary by age (mesor 37.32 ± 2.14 pg/mL).
Mean levels of CTX and P1NP were correlated (r = 0.65, p = 0.04). There were no other 
significant correlations between maximum or 24-h mean values of the metabolites (Table 2).
Discussion
Establishing the 24-h profile of serum sclerostin in relation to other bone biomarkers fills a 
knowledge gap in our understanding of the drivers of normal bone remodeling rhythms and 
how circadian disturbances could alter bone health. In this group of healthy men we found 
no significant 24-h rhythm in sclerostin. We verified the previously reported, robust 
sinusoidal rhythm of CTX, but found no evidence that sclerostin orchestrates the 24-h CTX 
rhythm. The timing of FGF-23 rhythmicity was variable across individuals and no 
statistically significant rhythm was identified in P1NP using cosinor analysis. This first 
published report of the 24-hour profile of serum sclerostin has implications for 
understanding the rhythmicity of bone turnover markers and the optimal collection time for 
sclerostin. Our results suggest that serum sclerostin, in contrast to CTX, can be measured at 
any time of day. Furthermore, these results do not support the hypothesis that osteocytes 
direct the rhythmicity of other bone turnover markers (CTX), at least not via a sclerostin 
mediated mechanism.
Previous studies have shown that the osteocyte plays a role in regulating osteoclast 
formation and activation and that increases in sclerostin (as occurs with mechanical 
unloading) stimulate osteoclast activity through increased expression of RANKL [5]. 
Therefore, one might expect sclerostin to display a 24-h profile similar to that of CTX and 
for these rhythms to be biologically linked. However, we found no clear peak or nadir in 24-
h sclerostin profiles using visual inspection or statistical analysis despite confirming the 
robust rhythmicity of CTX. This suggests the rhythmicity of CTX and bone resorption may 
be mediated by non-sclerostin mechanisms. These sclerostin data are in contrast to results 
reported in abstract form which identified a peak in sclerostin levels at 01:00 and a nadir at 
10:00 in young men (mean 26 years), using the same Biomedica sclerostin assay used in our 
study [13]. In that report, the activity and eating patterns of the 6 men were not described 
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and could have resulted in a more pronounced day-night pattern related to environmental/
behavioral influence, unrelated to the endogenous rhythmicity of CTX. Our analysis 
involved controlled lab conditions free of environmental and time cues. In this study food 
and activity were also carefully controlled - meals were scheduled and exercise prohibited 
(ambulation allowed). All 24-h profiles were in similar circadian phase. Samples obtained in 
these controlled lab conditions are more likely to detect the presence or absence of a 
universal, endogenous rhythmicity across individuals. The significant differences in the 24-h 
profiles of sclerostin and CTX identified in our study suggest that the rhythmicity in bone 
resorption reflected by CTX may be mediated by a non-sclerostin mechanism.
In contrast to sclerostin, we did find evidence of a rhythm in the osteocyte derived protein 
FGF-23. Although a sinusoidal rhythm was identified in FGF-23, there was more inter-
individual variation in phase (aka timing of peaks) than for CTX (see Fig 2d, polar plot). If 
FGF-23 rhythmicity were related to the regulation of dietary phosphate intake, one might 
expect more consistent timing in this study in which meal timing was aligned across 
individuals. This variable rhythm may present a challenge with clinical measurements and 
the establishment of normative values.
These data confirm the presence and timing of CTX 24-h rhythmicity but add to the 
conflicting reports of P1NP rhythmicity [2,14]. The fitted curves for serum P1NP appeared 
to have a diurnal profile when assessed visually on a magnified scale (Online Resource Fig 
1), albeit with a very small amplitude, and when rhythmicity was assessed by the Rao 
spacing test (Fig 2c polar plot), which tests whether the individuals’ peak times are 
clustered. However, no significant rhythm was identified with the more robust cosinor 
analysis. The variability in P1NP relative to an absent or relatively small amplitude rhythm 
and its long half-life (10 h) may limit the ability to detect a rhythm in these data [14].
It is interesting that rhythmicity appears diminished in cells of mesenchymal cell lineage 
(osteoblast, osteocyte) compared to cells of hematopoietic cell lineage (osteoclasts). Clock 
gene expression (Per1, Per2, Cry, Clock, BMAL1) in osteoclasts/blasts and the observation 
of altered bone mineral density in clock gene knockout animal models reinforces the concept 
of endogenous bone cell rhythmicity and the importance of peripheral clocks in bone cells 
and the rhythmic regulation of bone turnover in bone mass regulation [15-20]. Clock genes 
have not been identified in osteocytes and therefore, osteocyte rhythmicity is incompletely 
characterized. Our FGF-23 data suggest that a component of osteocyte function is rhythmic, 
but that timing varies between individuals. Additional research on the presence or absence of 
osteocyte clock genes and its relationships/regulation of the circadian rhythmicity of bone 
turnover in humans are needed to better characterize how sleep and circadian disruptions can 
affect bone metabolism at the cellular level.
Mean levels of CTX and P1NP were strongly correlated with one another but no other 
significant correlations were identified. Previous reports of the correlations between 
sclerostin and other markers have been conflicting [21-28] and may reflect variations in the 
sclerostin assays utilized [29,30], differences in participant sex/age, timing of sampling, 
presence/absence of metabolic bone diseases, use of blood vs. mRNA sclerostin levels, 
and/or analytic variability. In addition, studies of pre- and post-menopausal women suggest 
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race/ethnicity may affect BTM levels [31] and their associations with sclerostin [32]. Similar 
data in male populations are lacking but the correlations reported here may differ in other 
studies that have a larger, more ethnically diverse study population. It is unclear how well 
serum sclerostin correlates with mRNA levels in the bone [28,29] and therefore circulating 
levels may not reflect biologically relevant relationships. The differences in CTX, P1NP, and 
sclerostin levels by age are consistent with prior literature [4,33,28]. The relatively limited 
sample size (n = 4 older; n = 6 younger) limited the ability to detect differences in 
rhythmicity by age.
This analysis has several strengths. It is the first description of the 24-h profile of sclerostin 
and its relationship to the 24-h profiles of other bone biomarkers. The study involved a 
relatively large sample size (n = 10) for a complex sleep protocol. Since rhythmicity was 
confirmed in CTX and FGF-23, it is likely that we had adequate resolution (in sampling 
frequency and sample stability) to identify a meaningful rhythm in serum sclerostin. The 
study also has potential limitations. It is possible that sclerostin or P1NP day-night patterns 
are present but not detected by our methods. For instance, day/night patterns in sclerostin 
may be heavily influenced by environmental factors (such as light, food, or posture/
mechanical loading) that varied minimally in this study protocol. Furthermore, although a 
rhythm may have been apparent over a longer sampling interval (i.e. 48 h to obtain at least 2 
full periods), the rigorous design employed (with individuals aligned for differences in phase 
that account for meals and sleep opportunities) should have been capable of detecting a 
sinusoidal rhythm in the 24-h study interval. In addition, given the variability in 
commercially available sclerostin assays [29,30], use of a different assay (i.e. one that does 
not detect fragments as this Biomedica sclerostin assay does) and/or sample type (e.g. EDTA 
plasma) could yield different results. A cosinor model was chosen for this data analysis 
because the most robust bone biomarker rhythm (CTX) has a visually clear sinusoidal 
rhythm [1], as do other bone biomarkers [14,6]. Although a more complex rhythm may be 
present in sclerostin, the approach we used is the most appropriate for investigating the 
osteocyte-osteoclast rhythm relationship because it is presumed that endogenous rhythms of 
the bone biomarkers would be similar (i.e. both sine/cosine), if related. The samples reported 
here were taken from a baseline 24 h interval from a study intended to examine the 
metabolic effects of sleep disturbance [9] and not designed a priori to address bone-related 
questions. Nonetheless, the protocol appeared adequate to answer the bone questions posed 
herein. Due to limited resources, only healthy adult men were included in this analysis and 
therefore, sclerostin rhythmicity and its relationship to other bone biomarkers may be 
different in women or other groups. The duration of sample storage (4-8 years at −80°C) 
may have compromised our ability to detect rhythmicity in sclerostin. However, most 
proteins are stable at these temperatures. The half-life of circulating sclerostin is not known 
and if prolonged could limit the ability to detect a rhythm. Lastly, the serum values obtained 
in this study may not accurately reflect levels in the bone microenvironment [34].
Conclusions
In contrast to the robust diurnal rhythm of the bone resorption marker CTX, we found no 
significant rhythm in serum sclerostin in healthy adult men. Our results do not support the 
hypothesis that osteocytes direct the rhythmicity of other bone turnover markers (CTX), at 
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least not via a sclerostin mediated mechanism. These results also imply that time of day is 
less important when measuring serum sclerostin. The 24-h profile of FGF-23 suggests that a 
component of osteocyte function is rhythmic, but that timing varies between individuals.
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Fig 1. Study Protocol
Black bars depict sleep opportunities. Participants were admitted following a ≥ 21-day at-
home baseline stage of 10-h sleep opportunity per night. To further ensure participants were 
fully sleep satiated at time of sampling (horizontal orange bar), in-lab sleep opportunities 
were as follows: Days 1-3: 12 h/night; Days 2-4: an additional 4-h nap in the middle of the 
day; Day 4-6: 10 h/night. All clock times are presented as 24-h military time relative to 
breakfast, which occurred, on average, at 09:27 (SD 3 min). Figure adapted from Buxton et 
al STM 2012 [9].
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Fig 2. a-d 24-h serum profiles of (a) Sclerostin (b) CTX, (c) P1NP, and (d) FGF-23
For each biomarker, the left panel shows raw data for each individual’s 24-h serum profile (n 
= 10); the middle panel shows the fitted cosinor model for each individual (dotted) and for 
the group (solid) by age (older [dark red] vs. younger [light blue]; whole group in black for 
FGF-23 since there was no difference by age); right panel displays Polar plots displaying the 
time of biomarker peak for each of the 10 individuals with red/blue to depict older/younger 
age group, respectively, and distance from the center representing 24-h amplitude for the 
individual. In the graphs in left and middle panels, 10-h sleep opportunity is represented as a 
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horizontal black bar along the top of each graph and meal times are depicted by thin black 
vertical lines. Cosinor analysis and Rao spacing test are two different assessments of 
rhythmicity using a 24-h profile and one time point, respectively. Polar plots analyzed with 
Rao Spacing Test to assess clustering of peaks against the null hypothesis of peaks being 
evenly spaced along the circumference of the circle (representing 24-h). X-axis is in 
“Relative Clock Time” presented as 2-digit military time in hours relative to breakfast, 
which occurred, on average, at 09:27 (SD 3 min). No sinusoidal rhythm was identified in 
sclerostin (p = 0.99 for cosinor model, p > 0.10 for Rao spacing test). Cosinor model did not 
identify a significant rhythm in P1NP (p = 0.65), however Rao spacing test suggested time 
of peak was significantly clustered (p < 0.01). A significant rhythm was present in CTX and 
FGF-23 (both p < 0.001 in cosinor model). Visually, a clear peak and nadir can be seen for 
CTX even in the individuals’ raw data (left panel). No such rhythm can be seen in sclerostin. 
Younger men appear to have a greater amplitude and variability in CTX than older men but 
this was not statistically different (both p > 0.07). It can be appreciated visually in the fitted 
data (middle panel) that CTX has a greater amplitude than FGF-23. Similarly, as seen in all 
three panels, the acrophase, or time of peak level for FGF-23 is more variable than that of 
CTX (p for Rao spacing test p < 0.10 vs. p < 0.001, respectively).
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